MedTrace Logo

Study of NAV-240 in Healthy Volunteers

NCT06181786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-06-17

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

NAV-240

Intravenous administration of NAV-240

DRUG

Placebo

Intravenous administration of matching placebo for NAV-240

Sponsors & Collaborators

  • IMBiologics Corp.

    collaborator INDUSTRY

  • Navigator Medicines, Inc.

    lead INDUSTRY

Principal Investigators

  • Dana McClintock, MD · Navigator Medicines, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-22
Primary Completion
2024-09-04
Completion
2024-09-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06181786 on ClinicalTrials.gov